Genprex is a privately held, clinical-stage biopharmaceutical company focusing on developing breakthrough immunogene therapies with their lead product Oncoprex. Oncoprex is currently in a Phase II clinical trial for the treatment of stage IV non-small cell lung cancer in combination with Tarceva (erlotinib). The company was founded in 2009 and is headquartered in Austin, Texas.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/07/16 | undisclosed |
Inception Capital Management | undisclosed |
